RIVA-SILDENAFIL TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

SILDENAFIL (SILDENAFIL CITRATE)

可用日期:

LABORATOIRE RIVA INC.

ATC代码:

G04BE03

INN（国际名称）:

SILDENAFIL

剂量:

25MG

药物剂型:

TABLET

组成:

SILDENAFIL (SILDENAFIL CITRATE) 25MG

给药途径:

ORAL

每包单位数:

4/8/30

处方类型:

Prescription

治疗领域:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0136261001; AHFS:

授权状态:

CANCELLED PRE MARKET

授权日期:

2016-02-04

产品特点

PRODUCT MONOGRAPH
PR RIVA-SILDENAFIL
Sildenafil tablets (as sildenafil citrate)
25 mg, 50 mg and 100 mg
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
LABORATOIRE RIVA INC.
DATE OF PREPARATION:
660 Boul. Industriel
December 18, 2012
Blainville Québec
J7C 3V4
SUBMISSION CONTROL NO: 160584
_Riva-SILDENAFIL V Product Monograph Page 2 of 46_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND
PRECAUTIONS.........................................................................................
4
ADVERSE REACTIONS
..........................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................
10
DOSAGE AND ADMINISTRATION
.....................................................................................
14
OVERDOSAGE
.......................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 16
STORAGE AND
STABILITY.................................................................................................
19
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 19
PART II: SCIENTIFIC INFORMATION
.....................................................................................
21
PHARMACEUTICAL INFOR